glp-1 agonist in esrd Glucagon-like peptide 1(GLP-1) receptor agonists the management of the patient with type 2diabetes mellitus and chronic kidney disease: an approach for the nephrologist New Medications for Slowing CKD

Description

According to recent surveys from late 2025, approximately 12 percent of American adults have used GLP-1 medications such as Ozempic or Wegovy

Berberine and semaglutide is a popular combination that may have additive effects on blood sugar regulation but can also increase gastrointestinal side effects

However, it has a flaw: its half-life in the body is barely five minutes , severely limiting its effects

Due to their diverse structures, the pharmacokinetic profiles vary, and a prolonged half-life may be associated with an increased risk of adverse events